CA2147606C - Stable extended release oral dosage composition - Google Patents
Stable extended release oral dosage composition Download PDFInfo
- Publication number
- CA2147606C CA2147606C CA002147606A CA2147606A CA2147606C CA 2147606 C CA2147606 C CA 2147606C CA 002147606 A CA002147606 A CA 002147606A CA 2147606 A CA2147606 A CA 2147606A CA 2147606 C CA2147606 C CA 2147606C
- Authority
- CA
- Canada
- Prior art keywords
- coating
- core
- oral dosage
- approximate
- matrix core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
A film-coated extended release oral dosage composition containing the nasal decongestant pseudoephedrine or salt there-of, e.g., pseudoephedrine sulfate in a unique polymer matrix core and a film-coating on such core containing the non-sedating antihistamine, loratadine, and use of the said composition for treating patients showing the signs and symptoms associated with upper respiratory diseases and nasal congestion are disclosed.
Description
WO 94/09761 ' '~ ~ ~ ~ ~ ~ PCT/US93/09873 STABLE EXTENDED RELEASE ORAL DOSAGE COMPOSITION
BACKGROUND OF THE INVENTION
This invention relates to a film-coated extended release oral dosage composition containing the nasal decongestant pseudephedrine in a unique polymer matrix core and a film-coating on such core containing the non-sedating antihistamine, loratadine. The oral dosage composition of this invention is useful for treating patients showing the signs and symptoms associated with the common cold, upper respiratory diseases, allergic rhinitis and nasal congestion.
Loratadine is disclosed in USP 4,282, 233 as a non-sedating antihistamine and it is useful as an anti-allergy agent in, for example; the treatment of seasonal allergic rhinitis symptoms such as sneezing and itching.
Pseudephedrine as well as pharmaceutically acceptable acid additional salts, e.g., those of HCI or H2S04, is a sympathomimetic drug recognized by those skilled in the art as a safe therapeutic agent effective for treating nasal congestion and is commonly administered orally and concomitantly with an antihistamine for treatment of nasal congestion 2'~47~~~
associated with allergic rhinitis. 1=or example, 5 mg of loratadine and 120 mg of pseudoephedrine sulfate ('PES') in a matrix core repetab tablet product is available wherein the PES is equally distributed between the repetab tablet coating and barrier-coated core and wherein all the loratadine is in the coating. When the repetab tablet is placed in a stirred 0.1 N HCI solution such as found in the stomach, all of the PES, as well as all of the loratadine, present in the repetab tablet coating dissolve within a one hour period in the stirred acidic medium. None of the PES in the core dissolves in the acidic medium in that the barrier coating on the core is acid-resistant. A basic medium (a simulated inestinal fluid) is required to dissolve the core-coating and release the remaining 50% of PES over a five-hour period. The repetab product is recommended for twice-a-day dosing for effectiveness. U. S.
Patent 4,990,535 and 5,100,675 disclose a twice-a-day sustained release coated tablet wherein the tablet coating comprises loratadine, a hydrophilic polymer and polyethylene glycol, and the tablet core comprises acetaminophen, pseudoephedrine or a salt thereof, a swellable hydrophilic polymer and pharmaceutically acceptable excipients. Neither the twice-a-day sustained release tablet nor the twice-a-day repetab tablet makes obvious or discloses the once-a-day oral dosage composition of this invention.
The successful development of a formulation of a loratadine-pseudoephedrine once-a-day product would be desirable, but would require achieving a release rate profile for the pseudoephedrine component over an extended period in excess of twelve hours and preferably at least 16 hours while maintaining the safety and effectiveness of loratadine. Products containing non-sedating antihistamines in combination with WO 94/09761 ~ ~ ~ ~ ~ ~ PCT/US93/09873 pseudoephedrine such as Seldane-D, a press-coated product of terfenadine and pseudoephedrine and Hismanal-D, a combination of pseudoephedrine grills and a separate astemizole tablet are known, but do not make obvious the extended release composition of this invention. Furthermore, the administration of terfenadine and astemizole products to humans has been found to cause adverse effects including cardiac arrhythmias and occurrence of these arrhythmias have increased when the terfenadine or astemizole products are co-administered with other drugs such as ketoconazole and erythromycin or upon overdose of the non-sedating anti-histamine.
It would be desirable for increased patient compliance to have an extended release oral dosage loratadine-pseudoephedrine composition effective and safe when used on a once-a-day basis for the treatment, management and/or mitigation of the signs and symptoms associated with the common cold, upper respiratory diseases, allergic rhinitis and nasal congestion.
SUMMARY OF THE INVENTION
We have discovered that a film-coating of loratadine on a core tablet containing a pseudoephedrine salt, preferably pseudoephedrine sulfate, in a specific polymer matrix provides immediate release of loratadine and extended release of pseudoephedrine sulfate from the matrix core over a period in excess of twelve hours.
2147~D~
BACKGROUND OF THE INVENTION
This invention relates to a film-coated extended release oral dosage composition containing the nasal decongestant pseudephedrine in a unique polymer matrix core and a film-coating on such core containing the non-sedating antihistamine, loratadine. The oral dosage composition of this invention is useful for treating patients showing the signs and symptoms associated with the common cold, upper respiratory diseases, allergic rhinitis and nasal congestion.
Loratadine is disclosed in USP 4,282, 233 as a non-sedating antihistamine and it is useful as an anti-allergy agent in, for example; the treatment of seasonal allergic rhinitis symptoms such as sneezing and itching.
Pseudephedrine as well as pharmaceutically acceptable acid additional salts, e.g., those of HCI or H2S04, is a sympathomimetic drug recognized by those skilled in the art as a safe therapeutic agent effective for treating nasal congestion and is commonly administered orally and concomitantly with an antihistamine for treatment of nasal congestion 2'~47~~~
associated with allergic rhinitis. 1=or example, 5 mg of loratadine and 120 mg of pseudoephedrine sulfate ('PES') in a matrix core repetab tablet product is available wherein the PES is equally distributed between the repetab tablet coating and barrier-coated core and wherein all the loratadine is in the coating. When the repetab tablet is placed in a stirred 0.1 N HCI solution such as found in the stomach, all of the PES, as well as all of the loratadine, present in the repetab tablet coating dissolve within a one hour period in the stirred acidic medium. None of the PES in the core dissolves in the acidic medium in that the barrier coating on the core is acid-resistant. A basic medium (a simulated inestinal fluid) is required to dissolve the core-coating and release the remaining 50% of PES over a five-hour period. The repetab product is recommended for twice-a-day dosing for effectiveness. U. S.
Patent 4,990,535 and 5,100,675 disclose a twice-a-day sustained release coated tablet wherein the tablet coating comprises loratadine, a hydrophilic polymer and polyethylene glycol, and the tablet core comprises acetaminophen, pseudoephedrine or a salt thereof, a swellable hydrophilic polymer and pharmaceutically acceptable excipients. Neither the twice-a-day sustained release tablet nor the twice-a-day repetab tablet makes obvious or discloses the once-a-day oral dosage composition of this invention.
The successful development of a formulation of a loratadine-pseudoephedrine once-a-day product would be desirable, but would require achieving a release rate profile for the pseudoephedrine component over an extended period in excess of twelve hours and preferably at least 16 hours while maintaining the safety and effectiveness of loratadine. Products containing non-sedating antihistamines in combination with WO 94/09761 ~ ~ ~ ~ ~ ~ PCT/US93/09873 pseudoephedrine such as Seldane-D, a press-coated product of terfenadine and pseudoephedrine and Hismanal-D, a combination of pseudoephedrine grills and a separate astemizole tablet are known, but do not make obvious the extended release composition of this invention. Furthermore, the administration of terfenadine and astemizole products to humans has been found to cause adverse effects including cardiac arrhythmias and occurrence of these arrhythmias have increased when the terfenadine or astemizole products are co-administered with other drugs such as ketoconazole and erythromycin or upon overdose of the non-sedating anti-histamine.
It would be desirable for increased patient compliance to have an extended release oral dosage loratadine-pseudoephedrine composition effective and safe when used on a once-a-day basis for the treatment, management and/or mitigation of the signs and symptoms associated with the common cold, upper respiratory diseases, allergic rhinitis and nasal congestion.
SUMMARY OF THE INVENTION
We have discovered that a film-coating of loratadine on a core tablet containing a pseudoephedrine salt, preferably pseudoephedrine sulfate, in a specific polymer matrix provides immediate release of loratadine and extended release of pseudoephedrine sulfate from the matrix core over a period in excess of twelve hours.
2147~D~
Thus the present invention provides a film-coated extended release oral dosage composition comprising:
a. a matrix core comprising:
m r Pseudoephedrine Sulfate 120-360 Hydroxypropyl Methylcellulose 2208 100,000 cps 160-480 Ethylcellulose 40-120 Dibasic Calcium Phosphate Dihydrate 56-164 Povidone 20-60 Silicon Dioxide 6-12 and Magnesium Stearate 2~-Matrix Core Weight Range: 400-1200mg and b. a coating on said core comprising:
m I
Loratadine 5-15 Hydroxypropyl Methylcellulose 2910 6 cps 17-50 Polyethylene Glycol 400 0.25-5.0 Polyethylene Glycol 3350 .3.3 410.210.2 Approximate Coating Weight Range: 26-80mg Approximate Composition (Matrix core and coating) Weight Range: 426-1280mg In a preferred aspects, the present invention provides film-coated extended release oral dosage composition comprising a a. a matrix core comprising:
m core Pseudoephedrine Sulfate 240 Hydroxypropyl Methylcellulose 2208 100,000 cps. 160-480 Ethylcellulose 40-120 Dibasic Calcium Phosphate Dihydrate 56-164 Povidone 20-60 WO 94/09761 ~ ~ ~ PCT/US93/09873 m c r Silicon Dioxide 6-12 and 5 Magnesium Stearate Approximate Matrix Core Weight Range: 524-1082mg and b. a coating on said core comprising:
m I
Loratadine 10 Hydroxypropyl Methylcellulose 2910 6 cps. 17-50 Polyethylene Glycol 400 0.25-5.0 Polyethylene Glycol 3350 .3 4-10.15 Approximate Coating Weight Range: 31-75mg Approximate Composition(Matrix Core and Coating) Weight Range: 555-1157mg In a more preferred aspect, the present invention provides a film-coated extended release oral dosage composition comprising:
a. a matrix core comprising:
m core Pseudoephedrine Sulfate USP 240 Hydroxypropyl Methylcellulose 2208 USP 100,000 cps 320 Ethylcellulose NF Type 7 80 Dibasic Calcium Phosphate USP Dihydrate 108 Povidone USP 40 . Silicon Dioxide NF 8 and Magnesium Stearate NF 4 Approximate Matrix Core Weight: 800mg WO 94/09761 ~ ~ ~ ~ PCT/US93/09873 and b. a coating upon said core comprising:
ma/tablet Loratadine, Micronized ~ 10 Hydroxypropyl Methylcellulose 2910 USP 6 cps 33 Polyethylene Glycol 400 NF 0.67 Polyethylene Glycol 3350 NF 6.75 Color Dispersion (Solids) Approximate Coating Weight: 57mg Approximate Composition (Matrix Core and Coating) Weight: 857mg DETAILED DESCRIPTION OF THE INVENTION
We have discovered a unique oral dosage composition containing a specific selection of ingredients including specific amounts of a pseudoephedrine salt, preferably pseudoephedrine sulfate in a polymer matrix core and of loratadine in an immediate release polymer film coating on the core. The oral dosage composition of this invention provides (I) immediate release (i.e., within one hour after oral administration to a patient) of the total dose of loratadine to maintain the once-a-day efficacy of loratadine (2) the extended release of pseudoephedrine sulfate from the matrix polymer cover over a period of at least 12 preferably t2 to 16 hours and more preferably at least 16 hours from oral administration (3) reasonable dose size for enhancing patients' compliance and (4) a shelf life of at least 24 months.
In the course of development of the oral dosage composition of this invention, it was discovered that the selection of the specific polymers and of the specific ratios of such polymers for the polymer matrix core was critical WO 94/09761 ' ~ ~, ~ ~ ~ ~ PCT/US93/09873 to achieve the desired extended release period of at least 12 hours, preferably 12 to 16 hours and more preferably for at least 16 hours for pseudoephedrine sulfate. For example, the use of hydroxypropyl methyl cellulose 4,000 cps or 15,000 cps as polymers in the matrix core did not provide this more preferred extended release period of at least 16 hours for dose of pseudoephedrine sulfate. We discovered that only by selecting for inclusion into the matrix core specific weight ratios of three specific polymers was the desired pseudoephedrine release profile achieved. Only by combining {1 ) four parts by weight of hydroxypropyl methyl cellulose 2208 USP, 100,000 cps with (2) one part by weight of ethyl cellulose together with (3) one-half part by weight of povidone as a secondary binder was the more preferred extended release profile of at least 16 hours for pseudoephedrine sulfate from the matrix core achieved. The matrix core also contains specific amounts of silicon dioxide as a glidant and magnesium stearate as a lubricant. The tablet hardness 22 ~
6 Strong-Cobb Units (SCU) is not greatly affected by the higher level of lubricant (6mg/tablet) but it is preferred to maintain the lubricant level at part by weight of lubricant to one part by weight of povidone as secondary binder.
The hydroxyl propyl methyl cellulose 2910 acts as a film-forming agent in the film coating, and the polyethylene glycols act as plasticizers.
Other suitable film-forming polymers which may be used include hydroxypropyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose.
WO 94/09761 ~ ~o~ PCT/US93/09873 The oral dosage composition of this invention also provides a shelf life of more than 24 months, e.g., up to 36 and 48 months so long as the tablets are stored in standard package at between 2° and 30° C
in an ambient environment.
In the preparation of the tablet core the povidone is dissolved in a mixture of alcohol and water. The pseudoephedrine sulfate, hydroxypropyl methylcellulose 2208 USP, 100,000 cps, ethylcellulose, and dibasic calcium phosphate are blended and granulated with the alcoholic water solution containing povidone. The granulation is milled, and dried to a loss on drying between 0.5 to 2.0%.
The dried granulation is milled and blended with requisite amounts of silicon dioxide and magnesium stearate. The final blend is compressed to produce the oral dosage composition in the preferred form of a tablet.
The coating is normally applied to the tablet cores in the following manner:
Cores are charged into a suitable coating pan. A water dispersion of hydroxypropyl methylcellulose 2910 USP and polyethylene glycol 3350 NF is applied to the cores. These sub-coated cores are then coated with a dispersion of loratadine, hydroxypropyl methylcellulose 2910 USP, polyethylene glycol 3350 NF and white color dispersion. This is followed by an application of polishing coating dispersion containing hydroxypropyl WO 94/09761 ~.l l~' ~I ~ ~ PCT/US93/09873 methylcellulose and polyethylene glycol 400 NF. The coated tablets are then branded (with black ink) and packaged in plastic bottles and blisters for storage at a temperature between 2° and 30°C in an ambient environment This example illustrate preparation of the preferred oral dosage composition of this invention. The ingredients and specific amounts thereof are listed below.
I. Tablet Core A. Method of Manufacture I. Dissolve povidone in a mixture of alcohol and water.
2. Combine the pseudoephedrine sulfate, hydroxypropyl methylcellulose 2208, ethylcellulose and dibasic calcium phosphate, dihydrate in a suitable mixing bowl and blend.
3. Granulate the blend from Step 2 with the solution from Step. I. pass the wet granulation through a screen.
4. Dry the granulation to a loss on drying between 0.5 to 2.0% as determined by a moisture balance or equivalent.
2~g~~ ~0 -,o-5. Pass the dried granules through a screen.
6. Add the requisite amount of silicon dioxide and magnesium stearate to the dried, milled granules and blend.
a. a matrix core comprising:
m r Pseudoephedrine Sulfate 120-360 Hydroxypropyl Methylcellulose 2208 100,000 cps 160-480 Ethylcellulose 40-120 Dibasic Calcium Phosphate Dihydrate 56-164 Povidone 20-60 Silicon Dioxide 6-12 and Magnesium Stearate 2~-Matrix Core Weight Range: 400-1200mg and b. a coating on said core comprising:
m I
Loratadine 5-15 Hydroxypropyl Methylcellulose 2910 6 cps 17-50 Polyethylene Glycol 400 0.25-5.0 Polyethylene Glycol 3350 .3.3 410.210.2 Approximate Coating Weight Range: 26-80mg Approximate Composition (Matrix core and coating) Weight Range: 426-1280mg In a preferred aspects, the present invention provides film-coated extended release oral dosage composition comprising a a. a matrix core comprising:
m core Pseudoephedrine Sulfate 240 Hydroxypropyl Methylcellulose 2208 100,000 cps. 160-480 Ethylcellulose 40-120 Dibasic Calcium Phosphate Dihydrate 56-164 Povidone 20-60 WO 94/09761 ~ ~ ~ PCT/US93/09873 m c r Silicon Dioxide 6-12 and 5 Magnesium Stearate Approximate Matrix Core Weight Range: 524-1082mg and b. a coating on said core comprising:
m I
Loratadine 10 Hydroxypropyl Methylcellulose 2910 6 cps. 17-50 Polyethylene Glycol 400 0.25-5.0 Polyethylene Glycol 3350 .3 4-10.15 Approximate Coating Weight Range: 31-75mg Approximate Composition(Matrix Core and Coating) Weight Range: 555-1157mg In a more preferred aspect, the present invention provides a film-coated extended release oral dosage composition comprising:
a. a matrix core comprising:
m core Pseudoephedrine Sulfate USP 240 Hydroxypropyl Methylcellulose 2208 USP 100,000 cps 320 Ethylcellulose NF Type 7 80 Dibasic Calcium Phosphate USP Dihydrate 108 Povidone USP 40 . Silicon Dioxide NF 8 and Magnesium Stearate NF 4 Approximate Matrix Core Weight: 800mg WO 94/09761 ~ ~ ~ ~ PCT/US93/09873 and b. a coating upon said core comprising:
ma/tablet Loratadine, Micronized ~ 10 Hydroxypropyl Methylcellulose 2910 USP 6 cps 33 Polyethylene Glycol 400 NF 0.67 Polyethylene Glycol 3350 NF 6.75 Color Dispersion (Solids) Approximate Coating Weight: 57mg Approximate Composition (Matrix Core and Coating) Weight: 857mg DETAILED DESCRIPTION OF THE INVENTION
We have discovered a unique oral dosage composition containing a specific selection of ingredients including specific amounts of a pseudoephedrine salt, preferably pseudoephedrine sulfate in a polymer matrix core and of loratadine in an immediate release polymer film coating on the core. The oral dosage composition of this invention provides (I) immediate release (i.e., within one hour after oral administration to a patient) of the total dose of loratadine to maintain the once-a-day efficacy of loratadine (2) the extended release of pseudoephedrine sulfate from the matrix polymer cover over a period of at least 12 preferably t2 to 16 hours and more preferably at least 16 hours from oral administration (3) reasonable dose size for enhancing patients' compliance and (4) a shelf life of at least 24 months.
In the course of development of the oral dosage composition of this invention, it was discovered that the selection of the specific polymers and of the specific ratios of such polymers for the polymer matrix core was critical WO 94/09761 ' ~ ~, ~ ~ ~ ~ PCT/US93/09873 to achieve the desired extended release period of at least 12 hours, preferably 12 to 16 hours and more preferably for at least 16 hours for pseudoephedrine sulfate. For example, the use of hydroxypropyl methyl cellulose 4,000 cps or 15,000 cps as polymers in the matrix core did not provide this more preferred extended release period of at least 16 hours for dose of pseudoephedrine sulfate. We discovered that only by selecting for inclusion into the matrix core specific weight ratios of three specific polymers was the desired pseudoephedrine release profile achieved. Only by combining {1 ) four parts by weight of hydroxypropyl methyl cellulose 2208 USP, 100,000 cps with (2) one part by weight of ethyl cellulose together with (3) one-half part by weight of povidone as a secondary binder was the more preferred extended release profile of at least 16 hours for pseudoephedrine sulfate from the matrix core achieved. The matrix core also contains specific amounts of silicon dioxide as a glidant and magnesium stearate as a lubricant. The tablet hardness 22 ~
6 Strong-Cobb Units (SCU) is not greatly affected by the higher level of lubricant (6mg/tablet) but it is preferred to maintain the lubricant level at part by weight of lubricant to one part by weight of povidone as secondary binder.
The hydroxyl propyl methyl cellulose 2910 acts as a film-forming agent in the film coating, and the polyethylene glycols act as plasticizers.
Other suitable film-forming polymers which may be used include hydroxypropyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose.
WO 94/09761 ~ ~o~ PCT/US93/09873 The oral dosage composition of this invention also provides a shelf life of more than 24 months, e.g., up to 36 and 48 months so long as the tablets are stored in standard package at between 2° and 30° C
in an ambient environment.
In the preparation of the tablet core the povidone is dissolved in a mixture of alcohol and water. The pseudoephedrine sulfate, hydroxypropyl methylcellulose 2208 USP, 100,000 cps, ethylcellulose, and dibasic calcium phosphate are blended and granulated with the alcoholic water solution containing povidone. The granulation is milled, and dried to a loss on drying between 0.5 to 2.0%.
The dried granulation is milled and blended with requisite amounts of silicon dioxide and magnesium stearate. The final blend is compressed to produce the oral dosage composition in the preferred form of a tablet.
The coating is normally applied to the tablet cores in the following manner:
Cores are charged into a suitable coating pan. A water dispersion of hydroxypropyl methylcellulose 2910 USP and polyethylene glycol 3350 NF is applied to the cores. These sub-coated cores are then coated with a dispersion of loratadine, hydroxypropyl methylcellulose 2910 USP, polyethylene glycol 3350 NF and white color dispersion. This is followed by an application of polishing coating dispersion containing hydroxypropyl WO 94/09761 ~.l l~' ~I ~ ~ PCT/US93/09873 methylcellulose and polyethylene glycol 400 NF. The coated tablets are then branded (with black ink) and packaged in plastic bottles and blisters for storage at a temperature between 2° and 30°C in an ambient environment This example illustrate preparation of the preferred oral dosage composition of this invention. The ingredients and specific amounts thereof are listed below.
I. Tablet Core A. Method of Manufacture I. Dissolve povidone in a mixture of alcohol and water.
2. Combine the pseudoephedrine sulfate, hydroxypropyl methylcellulose 2208, ethylcellulose and dibasic calcium phosphate, dihydrate in a suitable mixing bowl and blend.
3. Granulate the blend from Step 2 with the solution from Step. I. pass the wet granulation through a screen.
4. Dry the granulation to a loss on drying between 0.5 to 2.0% as determined by a moisture balance or equivalent.
2~g~~ ~0 -,o-5. Pass the dried granules through a screen.
6. Add the requisite amount of silicon dioxide and magnesium stearate to the dried, milled granules and blend.
7. Compress the blend on a suitable tablet press.
During the compression operation, representative samples of the cores are taken and in-process tests are performed.
The core matrix meets the following specification:
Weight: 800 ~ 5% (mg) Thickness: 0.280 ~ 0.010 inches Hardness: 22 ~ 6 Strong-Cobb Units The cores are coated in the following manners:
A. Preparation of Coating Dispersions and Solutions I. Sub-Coating Solution (I) Disperse hydroxypropyl methylcellulose USP 2910 and polyethylene glycol 3350 in a portion of hot purified water.
~14'~6~~
_"_ (2) Add the remainder of the purified water and cool the solution to room temperature.
2. Active Coating Dispersion (I) Disperse hydroxypropyl methylcellulose USP 2910 and polyethylene glycol 3350 in a portion of hot purified water. Add additional water and cool the dispersion to room temperature.
(2) Disperse t_oratadine in the remaining portion of room temperature purified water. Combine with hydroxypropyl methylcellulose/polyethylene glycol dispersion (Step I).
(3) Add white color dispersion. Mix until uniform.
3. Polishing Coating Solution (I) Disperse hydroxypropyl methylcellulose USP 2910 and polyethylene glycol 400 in a portion of hot purified water.
{2) Add the remainder of the purified water and cool the solution to room temperature.
B. Coating of Tablet Core (I) Charge the requisite quantity of tablet cores to a suitable coating pan.
21~7~~~
(2) Apply the sub-coating solution.
(3) Quantitatively apply the active coating dispersion (4) Apply the polishing coating solution C. Br n in (I) Brand the coated tablets with black imprinting ink.
The preferred composition of the tablet core and coating is given below Tablet Matrix Core m r Pseudoephedrine Sulfate USP 240 Hydroxypropyl Methylcellulose 2208 USP 100,000 cps 320 Ethylcellulose NF Type 7 80 Dibasic Calcium Phosphate USP Dihydrate 108 Povidone USP 40 Silicon Dioxide NF 8 Magnesium Stearate NF 4 Approximate Matrix Core Weight: 800mg Tablet Coating ma/tablet t_oratadine, Micronized 10 Hydroxypropyl Methylcellulose 2910 USP 6 cps 33 Polyethylene Glycol 400 NF 0.67 Polyethylene Glycol 3350 NF 6.75 Color Dispersion (Solids) 6.25 Imprinting Ink _ Approximate Coating Weight: 57mg Approximate Tablet (Matrix Core and Coating) Weight: 857mg The in vi r dissolution profile of the tablet of Example I was measured in a stirred O.IN HCI solution at 37°C (1st hour) and thereafter (for ~I ~ 7~os an additional 15 hours) in a stirred phosphate buffer having a pH of 7.5 at 37°C. The loratadine in the coating was dissolved within the first hour and the total dose of pseudoephedrine sulfate in the core was slowly released via erosion and dissolution mechanisms over a period of at least 16 hours (see Table A hereinafter).
Similar results would be expected if a decongestant effective amount of another pharmaceutically acceptable pseudoephedrine salt, e.g., pseudoephedrine chloride were used in place of pseudoephedrine sulfate.
~, ~ ~~ __ TABLE A
IN VITRO DISSOLUTION PROt=ILE OF LORATADINE
AND PSEUDOEPHEDRINE SULFATE ~("PES")i FROM EXTENDED
RELEASE TABLETS OF EXAMPLE I
Dissolved Time. Hour Loratadine~ PE~b a Medium: 1000 ml O.IN HCL, 37°C; USP Paddle, 100 rpm;
average of 12 tablets.
b Medium: 1000 ml purified water, 37°C; USP Paddle, 100 rpm;
average of 12 tablets.
During the compression operation, representative samples of the cores are taken and in-process tests are performed.
The core matrix meets the following specification:
Weight: 800 ~ 5% (mg) Thickness: 0.280 ~ 0.010 inches Hardness: 22 ~ 6 Strong-Cobb Units The cores are coated in the following manners:
A. Preparation of Coating Dispersions and Solutions I. Sub-Coating Solution (I) Disperse hydroxypropyl methylcellulose USP 2910 and polyethylene glycol 3350 in a portion of hot purified water.
~14'~6~~
_"_ (2) Add the remainder of the purified water and cool the solution to room temperature.
2. Active Coating Dispersion (I) Disperse hydroxypropyl methylcellulose USP 2910 and polyethylene glycol 3350 in a portion of hot purified water. Add additional water and cool the dispersion to room temperature.
(2) Disperse t_oratadine in the remaining portion of room temperature purified water. Combine with hydroxypropyl methylcellulose/polyethylene glycol dispersion (Step I).
(3) Add white color dispersion. Mix until uniform.
3. Polishing Coating Solution (I) Disperse hydroxypropyl methylcellulose USP 2910 and polyethylene glycol 400 in a portion of hot purified water.
{2) Add the remainder of the purified water and cool the solution to room temperature.
B. Coating of Tablet Core (I) Charge the requisite quantity of tablet cores to a suitable coating pan.
21~7~~~
(2) Apply the sub-coating solution.
(3) Quantitatively apply the active coating dispersion (4) Apply the polishing coating solution C. Br n in (I) Brand the coated tablets with black imprinting ink.
The preferred composition of the tablet core and coating is given below Tablet Matrix Core m r Pseudoephedrine Sulfate USP 240 Hydroxypropyl Methylcellulose 2208 USP 100,000 cps 320 Ethylcellulose NF Type 7 80 Dibasic Calcium Phosphate USP Dihydrate 108 Povidone USP 40 Silicon Dioxide NF 8 Magnesium Stearate NF 4 Approximate Matrix Core Weight: 800mg Tablet Coating ma/tablet t_oratadine, Micronized 10 Hydroxypropyl Methylcellulose 2910 USP 6 cps 33 Polyethylene Glycol 400 NF 0.67 Polyethylene Glycol 3350 NF 6.75 Color Dispersion (Solids) 6.25 Imprinting Ink _ Approximate Coating Weight: 57mg Approximate Tablet (Matrix Core and Coating) Weight: 857mg The in vi r dissolution profile of the tablet of Example I was measured in a stirred O.IN HCI solution at 37°C (1st hour) and thereafter (for ~I ~ 7~os an additional 15 hours) in a stirred phosphate buffer having a pH of 7.5 at 37°C. The loratadine in the coating was dissolved within the first hour and the total dose of pseudoephedrine sulfate in the core was slowly released via erosion and dissolution mechanisms over a period of at least 16 hours (see Table A hereinafter).
Similar results would be expected if a decongestant effective amount of another pharmaceutically acceptable pseudoephedrine salt, e.g., pseudoephedrine chloride were used in place of pseudoephedrine sulfate.
~, ~ ~~ __ TABLE A
IN VITRO DISSOLUTION PROt=ILE OF LORATADINE
AND PSEUDOEPHEDRINE SULFATE ~("PES")i FROM EXTENDED
RELEASE TABLETS OF EXAMPLE I
Dissolved Time. Hour Loratadine~ PE~b a Medium: 1000 ml O.IN HCL, 37°C; USP Paddle, 100 rpm;
average of 12 tablets.
b Medium: 1000 ml purified water, 37°C; USP Paddle, 100 rpm;
average of 12 tablets.
Claims (5)
1. A film-coated extended release oral dosage composition comprising:
a. a matrix core comprising:
m-g/core Pseudoephedrine Sulfate 120-360 Hydroxypropyl Methylcellulose 2208 100,000 cps 160-480 Ethylcellulose 40-120 Dibasic Calcium Phosphate Dihydrate 56-164 Povidone 20-60 Silicon Dioxide 6-12 and Magnesium Stearate 2-6 Matrix Core Weight Range: 400-1200mg and b. a coating on said core comprising :
mg/tablet Loratadine 5-15 Hydroxypropyl Methylcellulose 2910 6 cps 17-50 Polyethylene Glycol 400 0.25-5.0 Polyethylene Glycol 3350 3.4-10.2 Approximate Coating Weight Range : 26-80mg Approximate Composition (Matrix Core and coating) Weight Range : 426-1280mg
a. a matrix core comprising:
m-g/core Pseudoephedrine Sulfate 120-360 Hydroxypropyl Methylcellulose 2208 100,000 cps 160-480 Ethylcellulose 40-120 Dibasic Calcium Phosphate Dihydrate 56-164 Povidone 20-60 Silicon Dioxide 6-12 and Magnesium Stearate 2-6 Matrix Core Weight Range: 400-1200mg and b. a coating on said core comprising :
mg/tablet Loratadine 5-15 Hydroxypropyl Methylcellulose 2910 6 cps 17-50 Polyethylene Glycol 400 0.25-5.0 Polyethylene Glycol 3350 3.4-10.2 Approximate Coating Weight Range : 26-80mg Approximate Composition (Matrix Core and coating) Weight Range : 426-1280mg
2. The use of pseudoephedrine sulfate in a matrix core and loratadine in a film coating for preparation of a film-coated extended release oral dosage composition for treating the signs and symptoms associated with upper respiratory diseases and nasal congestion.
3. The oral dosage composition of Claim 1 wherein 240 mg. of pseudoephedrine sulfate is in the matrix core and 10 mg. of loratadine is in the coating.
4. A film-coated extended release oral dosage composition comprising :
a. a matrix core comprising :
mg/core Pseudoephedrine Sulfate 240 Hydroxypropyl Methylcellulose 2208 100,000 cps. 160-480 Ethylcellulose 40-120 Dibasic Calcium Phosphate Dihydrate 56-164 Povidone 20-60 Silicon Dioxide 6-12 and Magnesium Stearate 2-6 Approximate Matrix Core Weight Range: 524-1082mg and b. a coating on said core comprising:
mg/tablet Loratadine 10 Hydroxypropyl Methylcellulose 2910 6 cps. 17-50 Polyethylene Glycol 400 0.25-5.0 Polyethylene Glycol 3350 3.4-10.2 Approximate Coating Weight Range: 31-75mg Approximate Composition (Matrix Core and Coating) Weight Range : 555-1157mg
a. a matrix core comprising :
mg/core Pseudoephedrine Sulfate 240 Hydroxypropyl Methylcellulose 2208 100,000 cps. 160-480 Ethylcellulose 40-120 Dibasic Calcium Phosphate Dihydrate 56-164 Povidone 20-60 Silicon Dioxide 6-12 and Magnesium Stearate 2-6 Approximate Matrix Core Weight Range: 524-1082mg and b. a coating on said core comprising:
mg/tablet Loratadine 10 Hydroxypropyl Methylcellulose 2910 6 cps. 17-50 Polyethylene Glycol 400 0.25-5.0 Polyethylene Glycol 3350 3.4-10.2 Approximate Coating Weight Range: 31-75mg Approximate Composition (Matrix Core and Coating) Weight Range : 555-1157mg
5. A film-coated extended release oral dosage composition comprising :
a. a matrix core comprising :
mg/core Pseudoephedrine Sulfate USP 240 Hydroxypropyl Methylcellulose 2208 USP 100,000 cps 320 Ethylcellulose NF Type 7 80 Dibasic Calcium Phosphate USP Dihydrate 108 Povidone USP 40 Silicon Dioxide NF 8 and Magnesium Stearate NF 4 Approximate Matrix Core Weight : 880mg and b. a coating upon said core comprising :
mg/tablet Loratadine, Micronized 10 Hydroxypropyl Methylcellulose 2910 USP 6 cps 33 Polyethylene Glycol 400 NF 0.67 Polyethylene Glycol 3350 NF 6.75 Color Dispersion (Solids) 6.25 Approximate Coating Weight 57mg Approximate Composition (Matrix Core and Coating) Weight : 857mg
a. a matrix core comprising :
mg/core Pseudoephedrine Sulfate USP 240 Hydroxypropyl Methylcellulose 2208 USP 100,000 cps 320 Ethylcellulose NF Type 7 80 Dibasic Calcium Phosphate USP Dihydrate 108 Povidone USP 40 Silicon Dioxide NF 8 and Magnesium Stearate NF 4 Approximate Matrix Core Weight : 880mg and b. a coating upon said core comprising :
mg/tablet Loratadine, Micronized 10 Hydroxypropyl Methylcellulose 2910 USP 6 cps 33 Polyethylene Glycol 400 NF 0.67 Polyethylene Glycol 3350 NF 6.75 Color Dispersion (Solids) 6.25 Approximate Coating Weight 57mg Approximate Composition (Matrix Core and Coating) Weight : 857mg
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/965,470 | 1992-10-23 | ||
| US07/965,470 US5314697A (en) | 1992-10-23 | 1992-10-23 | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
| PCT/US1993/009873 WO1994009761A1 (en) | 1992-10-23 | 1993-10-21 | Stable extended release oral dosage composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2147606A1 CA2147606A1 (en) | 1994-05-11 |
| CA2147606C true CA2147606C (en) | 2000-10-10 |
Family
ID=25510010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002147606A Expired - Lifetime CA2147606C (en) | 1992-10-23 | 1993-10-21 | Stable extended release oral dosage composition |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5314697A (en) |
| EP (1) | EP0665744B1 (en) |
| JP (1) | JP3580815B2 (en) |
| KR (1) | KR100283709B1 (en) |
| CN (1) | CN1038474C (en) |
| AT (1) | ATE161420T1 (en) |
| AU (1) | AU676229B2 (en) |
| CA (1) | CA2147606C (en) |
| CZ (1) | CZ287687B6 (en) |
| DE (1) | DE69316023T2 (en) |
| DK (1) | DK0665744T3 (en) |
| EE (1) | EE03106B1 (en) |
| ES (1) | ES2110633T3 (en) |
| FI (1) | FI112916B (en) |
| GR (1) | GR3026198T3 (en) |
| HK (1) | HK1004327A1 (en) |
| HU (1) | HU220629B1 (en) |
| IL (1) | IL107354A (en) |
| MY (1) | MY109090A (en) |
| NO (1) | NO308771B1 (en) |
| NZ (1) | NZ257447A (en) |
| PH (1) | PH29940A (en) |
| PL (1) | PL172862B1 (en) |
| SG (1) | SG42947A1 (en) |
| SK (1) | SK281090B6 (en) |
| TW (1) | TW251239B (en) |
| WO (1) | WO1994009761A1 (en) |
| ZA (1) | ZA937830B (en) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0804174A4 (en) * | 1993-07-21 | 1998-09-09 | Univ Kentucky Res Found | A multicompartment hard capsule with control release properties |
| US6818229B1 (en) | 1993-09-20 | 2004-11-16 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
| US6129930A (en) | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| US6676967B1 (en) * | 1993-09-20 | 2004-01-13 | Kos Pharmaceuticals, Inc. | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
| US6746691B2 (en) | 1993-09-20 | 2004-06-08 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
| US6080428A (en) | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| US7214683B1 (en) | 1994-12-30 | 2007-05-08 | Sepracor Inc. | Compositions of descarboethoxyloratadine |
| US7211582B1 (en) | 1994-12-30 | 2007-05-01 | Sepracor Inc. | Methods for treating urticaria using descarboethoxyloratadine |
| MX9706449A (en) * | 1995-02-28 | 1997-11-29 | Hoechst Marion Roussel Inc | Pharmaceutical composition for piperidinoalkanol compounds. |
| US5807579A (en) * | 1995-11-16 | 1998-09-15 | F.H. Faulding & Co. Limited | Pseudoephedrine combination pharmaceutical compositions |
| EP0811374A1 (en) | 1996-05-29 | 1997-12-10 | Pfizer Inc. | Combination dosage form comprising cetirizine and pseudoephedrine |
| IL129662A0 (en) * | 1996-10-31 | 2000-02-29 | Schering Corp | Composition for the treatment of asthma containing loratadine and a decongestant |
| PE71699A1 (en) * | 1997-02-07 | 1999-08-03 | Sepracor Inc | PHARMACEUTICAL COMPOSITION OF DECARBOETOXYLORATADINE WITHOUT LACTOSE, NON-HYGROSCOPIC AND ANHYDRA |
| BE1011045A3 (en) | 1997-03-14 | 1999-04-06 | Ucb Sa | Pharmaceutical composition for controlled release of active substances. |
| ATE238773T1 (en) * | 1997-08-26 | 2003-05-15 | Aventis Pharma Inc | MEDICINAL PRODUCTS FOR THE COMBINATION OF PIPERIDINOALKANOL-DECONGESTIVE |
| WO2000015226A1 (en) * | 1998-09-10 | 2000-03-23 | Schering Corporation | Antihistamines for treating non-infective sinusitis or otitis media |
| US6051585A (en) * | 1998-12-07 | 2000-04-18 | Weinstein; Robert E. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| US6521254B2 (en) | 1998-12-07 | 2003-02-18 | J-Med Pharmaceuticals, Inc. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| KR100505899B1 (en) * | 1999-02-23 | 2005-08-01 | 주식회사유한양행 | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine |
| WO2000050015A1 (en) * | 1999-02-23 | 2000-08-31 | Yuhan Corporation | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine |
| US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
| US6100274A (en) * | 1999-07-07 | 2000-08-08 | Schering Corporation | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
| US6267986B1 (en) * | 1999-09-24 | 2001-07-31 | Ranbaxy Laboratories Limited | Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine |
| US6114346A (en) * | 1999-10-22 | 2000-09-05 | Schering Corporation | Treating sleep disorders using desloratadine |
| AU2276801A (en) * | 1999-12-20 | 2001-07-03 | Schering Corporation | Extended release oral dosage composition |
| SK287684B6 (en) * | 1999-12-20 | 2011-06-06 | Schering Corporation | Sustained release solid oral pharmaceutical dosage composition |
| US7147870B2 (en) * | 2000-01-13 | 2006-12-12 | Osmotica Corp. | Osmotic device containing pseudoephedrine and an H1 antagonist |
| US6613357B2 (en) * | 2000-01-13 | 2003-09-02 | Osmotica Corp. | Osmotic device containing pseudoephedrine and an H1 antagonist |
| US7405223B2 (en) | 2000-02-03 | 2008-07-29 | Schering Corporation | Treating allergic and inflammatory conditions |
| AU4248400A (en) * | 2000-04-14 | 2001-10-30 | J Med Pharmaceuticals Inc | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| US20020094345A1 (en) * | 2000-10-06 | 2002-07-18 | Sara Abelaira | Pharmaceutical compositions containing epinastine and pseudoephedrine |
| AU2002220248A1 (en) * | 2000-11-06 | 2002-05-15 | Andrx Pharmaceuticals, Inc. | Once a day antihistamine and decongestant formulation |
| EP1401444A1 (en) * | 2001-06-20 | 2004-03-31 | Schering Corporation | Antihistamines for the treatment of nasal congestion and nasal obstruction |
| WO2004019917A1 (en) * | 2002-08-29 | 2004-03-11 | Osmotica Corp. | Device for release of a drug containing oseltamivir and a h1 antagonist |
| US6720002B2 (en) | 2001-07-20 | 2004-04-13 | R.P. Scherer Technologies, Inc. | Antihistamine formulations for soft capsule dosage forms |
| US6863901B2 (en) | 2001-11-30 | 2005-03-08 | Collegium Pharmaceutical, Inc. | Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
| US6827946B2 (en) * | 2001-12-05 | 2004-12-07 | Collegium Pharmaceutical, Inc. | Compositions containing both sedative and non-sedative antihistamines |
| US20040051686A1 (en) * | 2002-09-17 | 2004-03-18 | Yuan-Sung Weng | Carry-on device having functions of both digital photographing and timing |
| US8092831B2 (en) * | 2002-11-08 | 2012-01-10 | Andrx Pharmaceuticals, Llc | Antihistamine and decongestant system |
| US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
| AU2004314693B2 (en) | 2003-09-26 | 2011-04-07 | Alza Corporation | Drug coating providing high drug loading and methods for providing the same |
| US20050095288A1 (en) * | 2003-11-03 | 2005-05-05 | Andrx Labs, Llc | Decongestant and expectorant tablets |
| JP4999329B2 (en) * | 2003-12-01 | 2012-08-15 | 武田薬品工業株式会社 | Pre-printing method for solid preparation |
| US20050266032A1 (en) * | 2003-12-17 | 2005-12-01 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing multiple drugs |
| SE0401031D0 (en) | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
| US20060024368A1 (en) * | 2004-07-30 | 2006-02-02 | Reza Fassihi | Compressed composite delivery system for release-rate modulation of bioactives |
| AU2005325930B2 (en) * | 2005-01-27 | 2012-01-19 | Alembic Limited | Extended release formulation of Levetiracetam |
| US20070036859A1 (en) * | 2005-08-11 | 2007-02-15 | Perry Ronald L | Sustained release antihistamine and decongestant composition |
| KR101464771B1 (en) * | 2006-06-01 | 2014-11-26 | 머크 샤프 앤드 돔 코포레이션 | Pharmaceutical compositions for sustained release of phenylephrine |
| CN101015519B (en) * | 2007-02-27 | 2012-03-21 | 重庆医药工业研究院有限责任公司 | Loratadine oral compound medication composition |
| WO2008105920A1 (en) * | 2007-02-28 | 2008-09-04 | Collegium Pharmaceutical, Inc. | Antihistamine combination |
| US8173637B2 (en) * | 2008-07-24 | 2012-05-08 | Handa Pharmaceuticals, Llc | Stabilized atypical antipsychotic formulation |
| US20120065221A1 (en) | 2009-02-26 | 2012-03-15 | Theraquest Biosciences, Inc. | Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use |
| CA2690490C (en) | 2010-01-19 | 2012-06-26 | Accucaps Industries Limited | Pharmaceutical formulations of loratadine for encapsulation and combinations thereof |
| CN102160859B (en) * | 2011-02-23 | 2012-11-07 | 海南斯达制药有限公司 | Loratadine and pseudoephedrine compound slow-release medicament |
| JP5752578B2 (en) * | 2011-12-09 | 2015-07-22 | ジェイ−メド ファーマシューティカルズ，インコーポレーティッド | Single dose antihistamine / decongestant formulation for the treatment of rhinitis |
| CN104983708A (en) * | 2015-06-24 | 2015-10-21 | 万特制药(海南)有限公司 | Desloratadine sulfuric acid pseudoephedrine sustained release tablet and preparing method thereof |
| CN108576895B (en) * | 2018-03-06 | 2021-04-30 | 特素生物科技（天津）有限公司 | Slow-release nutritional staple food and preparation method thereof |
| EP4188339A1 (en) | 2020-07-30 | 2023-06-07 | Faes Farma, S.A. | Decongestant drug delivery system |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282233B1 (en) * | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
| US4601894A (en) * | 1985-03-29 | 1986-07-22 | Schering Corporation | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate |
| IE60311B1 (en) * | 1987-09-24 | 1994-06-29 | American Home Prod | Sustained release etodolac |
| CN1053570C (en) * | 1987-10-07 | 2000-06-21 | 默尔多药物公司 | Pharmaceutical composition for piperidinoalkanol-decongestant combination |
| US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
-
1992
- 1992-10-23 US US07/965,470 patent/US5314697A/en not_active Expired - Lifetime
-
1993
- 1993-10-21 EP EP93924327A patent/EP0665744B1/en not_active Expired - Lifetime
- 1993-10-21 PL PL93308491A patent/PL172862B1/en unknown
- 1993-10-21 DE DE69316023T patent/DE69316023T2/en not_active Expired - Lifetime
- 1993-10-21 SG SG1996001282A patent/SG42947A1/en unknown
- 1993-10-21 CA CA002147606A patent/CA2147606C/en not_active Expired - Lifetime
- 1993-10-21 IL IL107354A patent/IL107354A/en not_active IP Right Cessation
- 1993-10-21 KR KR1019950701529A patent/KR100283709B1/en not_active IP Right Cessation
- 1993-10-21 WO PCT/US1993/009873 patent/WO1994009761A1/en active IP Right Grant
- 1993-10-21 AT AT93924327T patent/ATE161420T1/en active
- 1993-10-21 PH PH47120A patent/PH29940A/en unknown
- 1993-10-21 CZ CZ19951014A patent/CZ287687B6/en not_active IP Right Cessation
- 1993-10-21 ZA ZA937830A patent/ZA937830B/en unknown
- 1993-10-21 AU AU54050/94A patent/AU676229B2/en not_active Expired
- 1993-10-21 NZ NZ257447A patent/NZ257447A/en not_active IP Right Cessation
- 1993-10-21 MY MYPI93002189A patent/MY109090A/en unknown
- 1993-10-21 ES ES93924327T patent/ES2110633T3/en not_active Expired - Lifetime
- 1993-10-21 SK SK522-95A patent/SK281090B6/en not_active IP Right Cessation
- 1993-10-21 HU HU9501143A patent/HU220629B1/en unknown
- 1993-10-21 DK DK93924327T patent/DK0665744T3/en active
- 1993-10-21 JP JP51111094A patent/JP3580815B2/en not_active Expired - Lifetime
- 1993-10-22 CN CN93118769A patent/CN1038474C/en not_active Expired - Lifetime
- 1993-10-22 TW TW082108823A patent/TW251239B/zh not_active IP Right Cessation
-
1994
- 1994-11-21 EE EE9400250A patent/EE03106B1/en unknown
-
1995
- 1995-04-21 FI FI951901A patent/FI112916B/en not_active IP Right Cessation
- 1995-04-21 NO NO19951527A patent/NO308771B1/en not_active IP Right Cessation
-
1998
- 1998-02-23 GR GR980400376T patent/GR3026198T3/en unknown
- 1998-04-23 HK HK98103388A patent/HK1004327A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2147606C (en) | Stable extended release oral dosage composition | |
| KR101234940B1 (en) | Stable extended release oral dosage composition | |
| JPH0228111A (en) | Pharmaceutical composition to piperidinoalkanol-ivprophene combination | |
| KR101464771B1 (en) | Pharmaceutical compositions for sustained release of phenylephrine | |
| US6994871B2 (en) | Once a day antihistamine and decongestant formulation | |
| KR101199654B1 (en) | Stable extended release oral dosage composition | |
| US20090162431A1 (en) | Sustained release formulations containing acetaminophen and tramadol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20131021 |